Danicamtiv Shows Promise in Genetic Dilated Cardiomyopathy

TR in HFpEF: Prognosis Varies by Mechanism

Vericiguat May Reduce Total Worsening HF Events

Mavacamten Reduces Biomarkers in nHCM: ODYSSEY-HCM Data

CMR Tracks ATTR-CM Progression and Treatment Response

AVR and ATTR Therapy Improve Survival in Dual Pathology

HFpEF-ABA Score Outperforms NT-proBNP in Trial Enrichment

Waist-to-Height Ratio Outperforms BMI in HFpEF Risk

PREVENT Equations Define 30-Year CVD Risk Percentiles

Beta-Blockers Cut MACE Risk Post-MI in Normal EF Patients